Despite the significant long-term impact of cCMV infection, there is limited evidence on which to base many treatment decisions in clinical practice. In an era of enhanced perinatal screening, fetuses and newborns are increasingly tested for CMV after abnormalities were detected during routine ultrasonography or maternal serology. Furthermore, otherwise "asymptomatic", congenitally CMV-infected, newborns are being identified after detection of SNHL through newborn hearing screening programs. Because of earlier diagnosis, babies with cCMV now presenting to pediatricians differ from those primarily included in clinical trials of treatment reported in the literature.
A symposium was convened during the 2015 conference of the European Society of Paediatric Infectious Diseases to discuss the current management of cCMV. In attendance were clinicians from throughout Europe, many of whom are involved in policy for cCMV for their region/country.
This article summarizes the discussions at this meeting alongside the evidence informing them. A balanced perspective of the controversies in this area is presented and areas of consensus highlighted. Finally, where evidence is lacking, suggestions are made for future research efforts to address areas of unmet medical need.
The authors acknowledge the coexisting need for studies on the management of babies with symptoms consistent with cCMV, but in whom this diagnosis cannot be firmly established, and of those with symptomatic postnatal CMV infection; this article does not, however, address these groups.
The internationally accepted GRADE system for evaluating evidence has been used to illustrate points where relevant (Table 1) . 3 
DEFINITIONS OF SYMPTOMATIC DISEASE
Classically, cCMV infection is categorized as "symptomatic" or "asymptomatic" at birth. Differing definitions and opinions on what constitutes "symptomatic" CMV infection, however, makes interpreting the literature challenging. Indeed, some of the largest cohort studies include babies with SNHL at birth in the group described as being "asymptomatic" because no "clinically apparent disease" was detectable during newborn examination. 4 In modern healthcare systems, whereby cCMV is increasingly detected through screening for other conditions, alongside increased accessibility of investigations, such as magnetic resonance imaging (MRI), the traditional dichotomy between clinically "apparent" and "inapparent" disease is becoming less meaningful. Table 2 summarizes the accepted clinical features of 11 Others have found only more extensive neuroimaging abnormalities to be of prognostic value. 13, 14 The majority at this meeting would not consider LSV in isolation to be a notable CNS manifestation of disease. It is suggested that neuroradiologic abnormalities not known to be clearly associated with CMV disease and adverse outcomes are discussed with a suitably experienced neuroradiologist, particularly, if the results of these discussions might influence treatment decisions. b. The exact pathophysiology of SNHL is not clear but is likely secondary to infection and degradation of sensory structures within the inner ear. 15, 16 It is therefore debated whether isolated SNHL should truly be considered a CNS manifestation of infection and, as a consequence, whether such children should be considered comparable to those with CNS disease included in published clinical trials. No studies have addressed this specific population, but a nonrandomized cohort study observing the effects of valganciclovir in isolated SNHL is in progress (clinicaltrials.gov NCT02005822). The majority of experts at this meeting would categorize babies with isolated, confirmed SNHL in the "severe"/CNS group because bilateral SNHL is not only associated with likely long-term impairments but was also included in the criteria for recruitment in the only randomized controlled trials (RCTs) in cCMV. However, consensus was not reached because the spectrum of hearing loss is wide, and treatment of isolated SNHL has not been evaluated in any RCTs.
WHEN SHOULD TESTING FOR CONGENITAL CMV BE CONSIDERED?
Indications for testing for cCMV are based on the presence of one or more of the most frequently observed clinical features (Table 3) . 17 Unfortunately, predictive values for each of these features are not available.
Full Consensus Within This Expert Group Was That Testing for cCMV Should be Performed in
1. Fetuses with ultrasound/MRI imaging consistent with cCMV disease (by appropriately timed antenatal testing of amniotic fluid). 18 (Quality C, Level 1) 2. Newborns where there is a maternal history of suspected primary CMV infection during pregnancy. If antenatal testing of amniotic fluid has been conducted, it is suggested that cCMV infection should still be confirmed at birth because both false-positive and -negative results have been reported. 18 (Quality C, Level 1) 3. Newborns with signs/symptoms consistent with cCMV disease (see Table 2 ; including those with findings consistent with cCMV on antenatal imaging). (Quality B, Strength 1) 4. Children with confirmed SNHL. 16 Systems need to be established to ensure testing for cCMV occurs, where possible, in the first 21 days of life because dried blood spot (DBS) are not always readily available for testing (see below). (Quality B, Strength 1)
The Majority Agreed That 5 . Newborns who are SGA should not routinely be tested. Studies in SGA newborns have shown the prevalence of cCMV to be 0%-5.2%. [19] [20] [21] [22] However, the majority of studies report a prevalence of 1.4%-1.8%, which is not significantly higher than the prevalence of cCMV in the general population. Therefore, evidence is insufficient to justify screening all newborns with isolated SGA for cCMV. None of these studies distinguish between asymmetrical (with normal head circumference) and symmetrical SGA, but when head circumference was mentioned, most SGA babies with cCMV had microcephaly (head circumference <−2 standard deviations). 21, 22 Because of this, and the poor prognostic outcome of children with cCMV and microcephaly, many present at this meeting test those babies with symmetrical SGA but not those with preserved head growth.
14 (Quality C, Strength 2) 6. Prematurity. Evidence that premature babies have a higher incidence of cCMV is limited. 20, 23 Testing extremely premature babies (<28 weeks gestational age) at birth does, however, assist in differentiating between congenital and postnatal infection. This may be very helpful in guiding the management of these babies that are particularly vulnerable to symptomatic postnatal infection. However, consensus was not reached regarding practice in this area, with cost being a factor among other considerations. 24 (Quality C, Strength 2) 7. Testing of babies born to mothers who are known to be CMV seropositive at the establishment of pregnancy. Although maternal nonprimary CMV infection is known to be important when considering the overall burden of cCMV disease, testing all babies born to these women, particularly in populations with high maternal seroprevalence, is tantamount to universal neonatal screening. 25, 26 Identifying women with nonprimary CMV who are at highest risk of transmitting infection to their fetus remains elusive. It was agreed that individual case discussion and local policy should therefore dictate practice in this area. Further research is clearly needed.
LABORATORY DIAGNOSIS OF CONGENITAL CMV INFECTION
Testing for cCMV using CMV polymerase chain reaction (PCR) in urine is highly reliable: sensitivity is 100% and specificity 99%. 27 One negative urine specimen in a neonate is therefore sufficient to exclude infection, and repeat sampling is not necessary. After 21 days, a urine positive for CMV could be because of CMV acquired postnatally from, for example, passage through the birth canal or through breast milk. As CMV PCR techniques are becoming more sensitive, earlier testing, before the age of 14 days, is recommended. 27 CMV PCR testing of saliva is an alternative and is easy to perform. Samples should be taken immediately before feeding in breastfed newborns, and confirmed with urine, as false-positive results have been reported. [28] [29] [30] [31] PCR assay of neonatal DBS can be performed retrospectively in an attempt to diagnose cCMV after the first 21 days of life. Sensitivity is around 84% in meta-analysis but is highly variable depending on the laboratory techniques used and the population being tested; a negative DBS PCR cannot, therefore, be used to definitively exclude a diagnosis of cCMV.
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Full Consensus Within This Expert Group Was That
1. Testing for cCMV should be performed using a single CMV PCR of urine obtained within 21 days of birth but ideally within 14 days of birth (Quality B, Strength 1). 2. Saliva PCR testing can be an alternative, but a positive result should be confirmed using urine (Quality B, Strength 1). 3. After the age of 21 days, CMV DNA PCR of stored DBS can be used to diagnose cCMV retrospectively; sensitivity is relatively low, and a negative test cannot be used to definitively exclude a diagnosis of cCMV (Quality B, Strength 1).
RECOMMENDED INVESTIGATIONS AFTER CONFIRMING A DIAGNOSIS OF CONGENITAL CMV INFECTION
After a virologic diagnosis of cCMV infection has been made, additional investigations are necessary to evaluate the extent of disease and to assist with discussions regarding prognosis and treatment.
Full Consensus Within This Expert Group Was That
1. The investigations below are conducted in any baby in whom a diagnosis of cCMV is confirmed, looking specifically for the manifestations of disease ( 
The Majority Agreed That
4. Cranial MRI should be performed in any babies with cCMV and evidence of CMV disease (see Table 2 ). (Quality C, Strength 1) 5. CMV PCR quantitation should be performed in blood at baseline. Several studies have shown the absence of CMV viremia to be associated with better longterm outcomes, and this may be reassuring when evaluating babies without any other manifestations of cCMV disease. [33] [34] [35] Blood CMV PCR should not, however, be used to rule out cCMV infection because, paradoxically, the absence of CMV in blood has been described even in babies with severe cCMV disease. 33, 36 (Quality C, Strength 2) 6. Examination of cerebrospinal fluid (CSF):
No current evidence supports examination of CSF as part of routine diagnostic work up. Studies have shown detectable CMV DNA in CSF, and elevated biomarkers such as β2-microglobulin suggest a poor prognosis. 13, 37 However, others have shown no additional prognostic value from CSF specimens obtained in the clinical setting. 37 Despite this lack of evidence, there was a majority view that although a possible area of interest for future research, lumbar puncture should not be performed routinely in babies with cCMV infection (Quality C, Strength 1). 
Only a Minority Agreed That
TREATMENT
No antiviral drugs are currently licensed for the treatment of cCMV. Although many case reports and cohort studies have reported on treatment for cCMV, there are results from only 2 RCTs. 7, [41] [42] [43] [44] The first of these studies evaluated 6 weeks' intravenous ganciclovir treatment in neonates (<1 month of age), gestational age ≥32 weeks and clinically apparent disease in the newborn period with evidence of CNS disease (including microcephaly, intracranial calcification, abnormal CSF indices for age, hearing deficit and chorioretinitis). 7 Improved hearing and neurodevelopmental outcomes were shown, but there was significant loss to follow-up. 7, 44 A more recent trial compared 6-week to 6-month treatment with oral valganciclovir and included babies with any evidence of symptomatic (including non-CNS) cCMV disease. 41 Few babies enrolled, however, had isolated, mild clinical features, and none in the 6-month treatment group had isolated SNHL (D Kimberlin 2015, personal email correspondence, 28 April). A modest benefit on both 2-year hearing and neurodevelopmental outcomes was shown with the 6-month treatment course. The longer treatment course improved likelihood of better hearing outcomes most notably in those with preexisting CNS involvement. Longer duration of therapy was only statistically significant, however, for "total ear" hearing as opposed to "best ear" hearing (which is of greater functional significance) and only once adjusted for baseline CNS involvement. Given the natural resolution of some features of cCMV disease in published cohorts, alongside the delayed onset of hearing loss and fluctuations in SNHL reported in cCMV, it is even more challenging to draw any conclusions regarding treatment effect from uncontrolled studies. 7, 16, 45 Clinical trials to date do not, therefore, provide good evidence on which to base treatment decisions for many of the infants presenting to clinicians in everyday clinical practice. Table 4 provides guidance on which infants should be offered treatment after a risk versus benefit discussion with the family. This table and associated text indicate areas where consensus was reached. Much discussion focused around the treatment of babies with less severe cCMV disease and whether the minimal additional benefit shown in the 6-month treatment course was sufficient to justify such a prolonged course of treatment.
Although clinical findings such as SGA and petechiae have been shown in historical cohorts to predict risk for SNHL, more recent reanalysis of data indicates that these findings in isolation are generally associated with disease-free outcomes in babies presenting without other manifestations of symptomatic disease. 9, 46 Opinion on the severity, or number, of symptoms justifying antiviral treatment remains divided, and it is therefore strongly recommended that clinicians discuss treatment initiation and duration with an expert in this area. 
Full Consensus Within This Expert Group Was That
Treatment of isolated SNHL:
The majority at this meeting would include SNHL at birth in their indications for treatment because this was in the inclusion criteria for treatment in previous RCTs. Furthermore, the main benefit of treatment is in preserving hearing rather than improving hearing once damage exists, with good outcomes reported in observational studies (with likely bias). 7, 41, 47 There was not, however, consensus, and it is acknowledged that no RCTs have specifically addressed treatment effect in this group of babies who are usually now identified through newborn hearing screening programs (Grade C, Strength 1). 8. Drug dose and formulation: Although oral valganciclovir is now first-line treatment in most cases, it is currently unknown whether valganciclovir reaches target areas as effectively as ganciclovir or, indeed, where drug should be targeted (eg, CNS or inner ear) because no studies have directly compared the 2 drugs. In those with severe disease, particularly if absorption is uncertain, intravenous ganciclovir is, therefore, preferred by some in early stages of treatment until oral therapy can be reliably tolerated (Quality C, Strength 1). 9. Treatment duration in cases without CNS involvement: In those infants in whom the decision is taken to give antiviral treatment, the majority would treat for 6 months. However, there was no consensus on this point in light of the modest benefit shown for longer treatment courses in the only RCT (Quality B, Strength 2).
Treating babies older than 28 days:
Treatment of older children has not been addressed in any RCTs, although it is acknowledged that the 28-day cutoff is also not evidence based. Retrospective case series of small numbers of babies treated outside the newborn period have reported good outcomes. 48, 49 Babies found to have SNHL after hearing screening at birth often do not have a diagnosis of cCMV confirmed until outside the 1-month "window of evidence" for treatment. No consensus was reached on how late it might be acceptable to start treatment in this scenario, or in the eventuality of hearing deterioration. Two RCTs are currently evaluating the use of treatment in older children with cCMV and SNHL (clinicaltrials.gov NCT01649869 and NCT02606266), which may clarify this debate. (Evidence for treating outside the newborn period Quality D, Strength 2.)
SIDE EFFECTS OF ANTIVIRAL TREATMENT
Much of the debate around treating less severely affected babies relates to the potential side effects of currently available antiviral drugs.
Significant neutropenia is frequently observed during antiviral treatment in infants. This is reported less commonly with valganciclovir than with ganciclovir (21% compared with 65%). 7, 41, 44, 50 Neutropenia generally occurs during the first month of treatment, with no increased toxicity observed after 6 weeks in those randomized to receive 6-month treatment compared with placebo in the only RCT evaluating this. 41 The oral administration of valganciclovir also removes the burden of hospitalization and risk of nosocomial infections and central line complications observed during treatment with ganciclovir. Hepatotoxicity has been reported in up to 30% of those treated with ganciclovir and thrombocytopenia in a similar proportion. 51 In the most recent study of treatment with valganciclovir, deranged liver function was observed, but this was neither clinically nor statistically significant when compared with placebo. In all studies, abnormal biochemical and hematologic parameters resolved after drug discontinuation.
Long-term side effects have not been evaluated in neonates treated with ganciclovir or valganciclovir. Animal studies raise the theoretical risk of gonadotoxicity and carcinogenicity. 52, 53 Although this has not been observed in humans to date, parents should be counseled about these potential risks, particularly when considering treatment in those groups in which benefit has not been clearly shown. No adverse long-term effects have been documented in a small cohort of babies treated in early neonatal studies and followed up to puberty (NCT00031421, unpublished data). Table 5 summarizes a proposed monitoring strategy for babies treated for cCMV. These recommendations are based on the safety monitoring and data obtained from the published RCTs. There is currently only evidence for starting treatment in the first month of life. *Limited evidence without full consensus: see text for further description. †In the case of isolated, nonspecific MRI findings that are not consistent with cCMV disease, it was agreed that treatment is not necessarily indicated. ‡It was suggested (without consensus) that treatment might continue in this group until the underlying clinical manifestation of disease (eg, hepatitis) resolved because benefit of 6 months treatment is unclear.
MONITORING OF BABIES DURING TREATMENT
§No studies address this particular group, although they were included in eligibility criteria for treatment in both published RCTs of treatment.
There are no data to support therapeutic drug monitoring. 54 Therapeutic drug monitoring may, however, have a role when toxicity is a concern (eg, in those with impaired renal function) or where there are concerns about treatment response.
Full Consensus Within This Expert Group Was That
1. Where treatment is given, babies should have regular weight measurement and safety monitoring to enable appropriate dose adjustment of medication (see Table 5 ).(Quality A, Strength 1) 2. Where treatment is given, parents should be fully counseled about both the known and potential side effects of treatment with current antivirals. (Quality A, Strength 1 for short-term side effects; Long-term, no published studies) 3. Although there are theoretical risks of longer term treatment toxicity, no large cohorts have been followed up to enable this to be fully evaluated in humans treated during early life. Where possible, children receiving antiviral treatment should, therefore, be entered into a registry to enable ongoing pharmacovigilance.
Only a Minority Agreed That
1. Viral load monitoring: Some centers report monitoring viral load to assist in decisions regarding adequate drug dosing and detection of potential drug resistance; however, most experts at this meeting do not conduct this routinely. Treatment duration is not altered by any viral parameters, and rebound of virus after treatment discontinuation is well documented with no demonstrable association with longterm outcomes (Quality D, Strength 2). If viral load is checked after discontinuing drug, it is suggested that parents are forewarned of the likelihood that virus will be detectable and that this is of unknown significance. Table 5 summarizes recommended follow-up of babies with cCMV (both treated and untreated).
FOLLOW-UP
The recommendation for audiologic follow-up is based on long-term surveillance studies of SNHL in cCMV. 4, 16 Frequent follow-up is suggested during the first 2 years of life because this is the period of highest risk for development of cCMV-associated hearing loss and a critical period for language development. Early detection of SNHL during this period is also most likely to improve longterm outcomes. 55 Monitoring should continue into early childhood, however, because deterioration in hearing continues throughout early life 55 (Quality B, Strength 1). Neurodevelopmental follow-up is suggested at 1 and 2 years of age ideally with formal neurodevelopmental assessment. This is not, however, routinely conducted in all centers, and there is no evidence-based benefit in this particular group, although early detection of functional impairments is generally agreed to be beneficial.
Ophthalmic follow-up is recommended annually at least until children can talk in those with clinically detectable disease at birth, but not in those without, because deterioration in vision has been observed in this group (Quality C, Strength 1). 6 Families should be given information for local/national support groups where these exist (see acknowledgements). Where cCMV parent groups are not easily accessible, parents of children with hearing loss may find support from groups for those with hearing impairment. 
CONCLUSIONS
As stated at the outset, this article represents the consensus opinion of a group of professionals with a particular interest in cCMV. It highlights that much of our practice is based on limited data but identifies areas where there is nonetheless consensus amongst experts.
Recent publications have shown potential cost effectiveness of screening at birth for cCMV, although these calculations are constrained by the issues raised in this article regarding true quantification of benefits of treatment and agreed treatment duration in certain patient groups. 56, 57 It will be challenging to address many of the research questions raised through RCTs, given the significant resources and long-term follow-up required alongside potential difficulties in recruiting into such studies when treatment is anecdotally being offered more freely. Collecting accurate data on disease manifestations and treatment outcomes in different patient groups alongside maternal demographics can, however, inform treatment strategies as previously shown very effectively for the management of pediatric human immunodeficiency virus. This requires a unified approach to initial diagnostic tests, definitions of symptomatology and follow-up which is currently being addressed by a network of clinicians with an interest in this area through both national and European initiatives such as Paediatric European Network for Treatment of AIDS -Infectious Diseases, the European Congenital CMV Initiative and European Society of Paediatric Infectious Diseases and European Society for Clinical Virology (ESCV). It should also be reiterated that this article focuses on postnatal aspects of diagnosis and treatment. There is an associated and simultaneous need for work alongside obstetric and fetal medicine colleagues to address similar uncertainties in aspects of antenatal care. It is hoped that through such collaborations, progress will be made in decreasing infection and disease in fetuses, newborns and subsequently older children with cCMV.
